AD
Alemnew F. Dagnew

Publications (1)

A phase I, open-label trial on the safety and immunogenicity of the adjuvanted tuberculosis subunit vaccine H1/IC31® in people living in a TB-endemic area
Article scientifique · 2018

Domaines principaux

Sciences de la santé1

Statistiques

Consultations4
Téléchargements0